CLAIMS

What is claimed is:

1. An isolated, substantially enantiomerically pure compound selected from the group consisting of:



1S



2S



2R



3S

or a pharmaceutically acceptable salt thereof.

2. An enantiomeric compound selected from the group consisting of:



1S



2S



2R



3S

or a pharmaceutically acceptable salt thereof, wherein the enantiomeric compound is present in an enantiomeric mixture having at least 90%, at least 95%, or at least 99% of the enantiomeric compound.

3. The compound of claim 1 or 2, wherein the compound is:



1S

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 or 2, wherein the compound is:



2S

,

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 or 2, wherein the compound is:



2R

,

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 or 2, wherein the compound is:



3S

,

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a compound of any one of claims 1-6 and a pharmaceutically acceptable excipient.

8. The pharmaceutical composition of claim 7, wherein the composition is an oral composition.

9. A composition comprising an enantiomeric mixture of a compound selected from the group consisting of:



1 , **2** , and **3** ,

or a pharmaceutically acceptable salt thereof, wherein the enantiomeric mixture has a significantly greater amount of the enantiomer having the higher binding affinity at the NMDA receptor MK-801 site.

10. A composition comprising an enantiomeric mixture of the compound:



2

,

or a pharmaceutically acceptable salt thereof, wherein the enantiomeric mixture has a significantly greater amount of the enantiomer having the lower binding affinity at the NMDA receptor MK-801 site.

11. Use of an effective amount of a compound or composition of any one of claims 1-10 in the manufacture of a medicament for treating depression, anxious depression, a mood disorder, an anxiety disorder, or a substance use disorder and any symptom or disorders associated therewith in a subject in need thereof, wherein said medicament is to be administered to the subject in need thereof.

12. The use of claim 11, wherein the compound or composition is to be orally administered.

13. Use of an effective amount of a compound or composition of any one of claims 1-10 in the manufacture of a medicament for treating depression or anxious depression in a subject in need thereof, wherein said medicament is to be administered to the subject in need thereof.

14. The use of claim 13, wherein the compound or composition is to be orally administered.

15. Use of an effective amount of a compound selected from the group consisting of:



1 , **2** , and **3** ,

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating depression, anxious depression, a mood disorder, an anxiety disorder, or a

substance use disorder and any symptom or disorders associated therewith in a subject in need thereof, wherein said medicament is to be administered to the subject in need thereof.

16. The use of claim 15, wherein the compound or composition is to be orally administered.

17. A compound or composition of any one of claims 1-10 for use as a medicament.

18. A compound selected from the group consisting of:



1

,



2

, and



3

,

or a pharmaceutically acceptable salt thereof, for use as a medicament.